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Abstract
Purpose of Review Pre-operative endocrine therapy can be
used to down-stage large or locally advanced breast cancers
in ER+ disease. In the last four decades, it has evolved from a
treatment perceived as an alternative to surgery for those too
unfit to undergo surgery or chemotherapy, to the present day
where it is a valuable and valid option in the treatment of
postmenopausal women with ER-rich (Allred score 7–8, or
> 50% staining for ER) breast cancer.
Recent Findings Emerging data from the metastatic setting is
translating into neoadjuvant trials, utilising dual endocrine
targeting or combinations of endocrine agents and other
targeted drugs, including those acting against components of
the PI3K pathway and the cell cycle. The routine use of peri-
operative endocrine therapy in all ER+ tumours may help to
yield important long-term prognostic information, and guide
adjuvant endocrine therapy.
Summary Pre-operative endocrine therapy is an exciting and
evolving area with emerging new approaches. In this review,
established evidence and emerging data on its applications are
discussed.
Keywords Breast cancer . Neoadjuvant . Endocrine therapy .
Aromatase inhibitor . Pre-operative . Tamoxifen
Introduction
Approximately 75% of all invasive breast cancers express
oestrogen receptor alpha (ER+), a favourable prognostic
factor and a strong predictor of response to endocrine
therapies. In early breast cancer, treatment usually in-
cludes surgery, followed by adjuvant (post-operative)
treatments, involving one or more of chemotherapy, en-
docrine therapy, radiotherapy and anti-HER2-targeted
therapies in appropriate patients. Neoadjuvant therapy re-
fers to treatment given prior to surgery and can be used
to down-stage large or locally advanced breast tumours,
making initially unresectable disease become operable [1]
and increasing the likelihood of successful breast conser-
vation surgery [2]. Neoadjuvant chemotherapy became
established as an option for many women with breast
cancer following studies in the 1970s and 1980s. There
is now increasing evidence for the role of neoadjuvant
endocrine therapy as an alternative in ER+ breast cancers,
especially in postmenopausal women [3]. This review
will focus on the evidence available for neoadjuvant en-
docrine therapies in ER+ breast cancer.
Application of Neoadjuvant Therapy in Breast
Cancer
Neoadjuvant therapy allows patients with large operable and
locally advanced breast cancer who respond well to treatment
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to be suitable for breast conservation surgery at a later date. A
further advantage is the unique in vivo observation of tumour
response to treatment [4]. This can identify patients who do
not respond to a particular drug, allowing a switch to an alter-
native or combination approach, or indeed proceeding to sur-
gery rather than continuing with neoadjuvant systemic thera-
py. Ultimately, this has potential to spare patients from unnec-
essary and ineffective treatments. It also allows a unique op-
portunity to explore potential biomarkers associated with re-
sponse or resistance through sequential biopsies taken on
treatment in the neoadjuvant period. Longer-term prognostic
information can also be derived in this early period. Response
in the neoadjuvant setting is reported by varying methods
between trials, including clinical response (measured by clin-
ical calliper examination, or amenability to breast conserva-
tion surgery as assessed by a breast surgeon), radiological
response (tumour volume as assessed by imaging, including
mammography, ultrasound or magnetic resonance imaging
(MRI)) or pathological response (assessed on sequential biop-
sy by reduction in Ki67). Pathological complete response
(pCR, an absence of invasive and in situ disease after treat-
ment) is associated with favourable prognosis with improved
long-term disease-free and overall survival; especially in
HER2-positive and triple-negative breast cancer subtypes
[5], however, it is attained less frequently with neoadjuvant
endocrine therapy than with chemotherapy.
Indications for Neoadjuvant Endocrine Therapy
Patients who may be candidates for neoadjuvant treatment
include those with large operable primary cancers greater than
5-cm diameter (T3), or any cancer that is not immediately
amenable to breast conservation surgery due to its size, cancers
with skin or chest wall involvement (T4), or those with in-
volved axillary lymph nodes at diagnosis (N1–2) [6]. There
are also circumstances where women with smaller primary
tumours may be considered for neoadjuvant therapy, such as
if they wish to undergo breast conservation surgery rather than
mastectomy and/or have a small breast to tumour size ratio [7].
In premenopausal women in whom neoadjuvant therapy is
deemed necessary, chemotherapy rather than endocrine thera-
py is currently recommended. If chemotherapy is not an op-
tion due to patient preference or comorbidities, premenopaus-
al patients should proceed to surgery rather than receiving
neoadjuvant endocrine therapy. There have been studies of
neoadjuvant endocrine therapy in premenopausal women,
and it appears that it is effective in shrinking cancers; however,
the sample numbers in published studies are too small and are
lacking in long-term clinical outcome data, to be certain that
this is a safe option [8]. In postmenopausal women with lo-
cally advanced breast cancer, neoadjuvant chemotherapy is
widely used, but in women with ER-rich HER2-negative
disease, neoadjuvant endocrine therapy is an appropriate al-
ternative. Judicious review with serial examination and imag-
ing to assess response to neoadjuvant endocrine therapy is
required in these patients, and an alternative approach (a
switch in endocrine agent or surgery) is required if there is
suggestion of disease progression. Ameta-analysis comparing
neoadjuvant endocrine therapy with neoadjuvant chemother-
apy in 20 randomised controlled trials of 3490 women found
similar response rates with neoadjuvant endocrine therapy and
neoadjuvant chemotherapy, but lower toxicities associated
with endocrine therapy. Neoadjuvant endocrine monotherapy
with an aromatase inhibitor compared with neoadjuvant com-
bination chemotherapy achieved similar clinical response rate
(odds ratio (OR) 1.08, 95% CI 0.5–2.35, p = 0.85), radiolog-
ical response rate (OR 1.38, 95% CI 0.92–2.07, p = 0.12) and
breast conservation surgery rate (OR 0.65, 95% CI 0.41–1.03,
p = 0.07) but with lower toxicity [9]. Most studies included in
this meta-analysis did not directly compare endocrine therapy
with chemotherapy, but rather two endocrine agents or an
endocrine agent with or without growth factor pathway
inhibitors.
Attainment of pCR after neoadjuvant therapy correlates
to improved event-free and overall survival [10]. ER+
(luminal) tumours have a more favourable prognosis over-
all than other more proliferative breast cancer subtypes.
However, the rate of pCR achieved with neoadjuvant che-
motherapy is less in luminal disease than that in triple-
negative or HER2-positive disease. In one study of 107
patients treated with neoadjuvant anthracycline-based che-
motherapy, only 7% of luminal disease attained pCR com-
pared to 36% of HER2+/ER− (< 5% ER staining) tumours
and 27% of triple negative tumours (p = 0.01) [11]. The
degree of response to neoadjuvant chemotherapy is also
inversely related to the level of ER expression, with a sig-
nificantly higher rate of pCR in patients with ER- and PR-
negative disease (17.7%), compared with those with low
expression (0–49% staining) of ER and PR (3.3%), and
those with high expression (> 50% staining) of ER and
PR (0%; odds ratio 14.4, p < 0.001) [12]. Indeed, the sur-
vival advantage offered by adjuvant chemotherapy in lu-
minal A breast cancer (ER-rich, HER2-negative, low pro-
liferative) is doubtful. The International Breast Cancer
Study Group IX trial found no survival advantage of cy-
clophosphamide, methotrexate and 5-fluorouracil followed
by tamoxifen, over tamoxifen alone, in 1669 postmeno-
pausal women with ER+ node-negative breast cancer at
13.1 years follow-up (64 vs 66%, p = 0.99) [13].
Therefore, this cohort of patients may be able to safely
avoid chemotherapy and its associated toxicities [14], and
these women may be candidates for neoadjuvant endocrine
therapy, if neoadjuvant therapy is deemed necessary.
The rate of pCR in response to neoadjuvant endocrine
therapy in postmenopausal women with ER+ disease is not
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significantly superior to the rate of pCR with chemotherapy
in ER+ disease (3 vs 6% in one study of 239 patients [8] and
< 10% overall in the 20 study meta-analysis [9]). However,
the rate of breast conservation surgery is improved (33 vs
24%, p = 0.058) [8]. This highlights the limitation of using
pCR after neoadjuvant therapy to predict outcome in ER+
disease. The better outcomes in this cohort are largely due
to the benefit of adjuvant endocrine therapy. The use of
tamoxifen as a neoadjuvant agent was first described in
the 1970s as an alternative to surgery in elderly patients
with comorbidities [15], where it was used as primary
endocrine therapy as an alternative to surgery, rather than
a neoadjuvant approach. A meta-analysis of 7 trials and
1571 elderly patients found no overall survival advantage
of surgery over primary endocrine therapy in this cohort
(hazard ratio (HR) 0.98, p = 0.9). It did show however a
benefit in progression-free survival in favour of surgery
followed by adjuvant endocrine therapy over primary en-
docrine therapy alone (HR 0.55, p = 0.0006) [16].
Therefore, traditionally neoadjuvant endocrine therapy
was reserved for patients deemed too frail to undergo
surgery or receive chemotherapy. However, the undisput-
ed benefit of endocrine therapy in the adjuvant setting in
ER+ disease has driven the exploration and increasing use
of endocrine agents in the neoadjuvant setting. The in-
creasing use of the aromatase inhibitors (AIs), and their
superior tolerability over chemotherapy, has proved an
effective and safe option as neoadjuvant therapy followed
by surgery, for select postmenopausal women [17].
Tumours that are most likely to respond to neoadjuvant
endocrine therapy are ER-rich (Allred score 7–8, or > 50%
staining for ER), with a low proliferative index (Ki67
< 10–15%). Response also correlates to level of ER expres-
sion. In one study of 324 postmenopausal women, re-
sponse to neoadjuvant letrozole was more than 60%, and
to tamoxifen 45%, in patients with Allred scores of 7–8,
compared to 0% in Allred scores 0–2 [18]. Postmenopausal
women with ER-rich, HER2-negative primary breast can-
cers may be treated with neoadjuvant endocrine therapy. In
elderly and frail patients, neoadjuvant endocrine treatment
may down-size a primary breast cancer to allow a less
extensive resection under local anaesthesia in the future
[19]. In patients who are deemed so frail that they are
unlikely to ever be considered as surgical candidates, re-
gardless of response to neoadjuvant therapy, or whose life
expectancy is likely to be limited by an illness other than
breast cancer, up-front primary endocrine therapy is a rea-
sonable approach [20] and can be continued for months to
years. The same agent can be used long term so long as
disease is responsive or stable, and a switch to an alterna-
tive agent can be considered if there is evidence of disease
progression, which is likely eventually in the absence of
definitive local therapy.
Neoadjuvant Endocrine Therapies; Tamoxifen
or Aromatase Inhibitors?
Postmenopausal Women
The third-generation aromatase inhibitors (AIs) letrozole,
anastrozole and exemestane have become established in the
care of ER+ breast cancer in the adjuvant setting due to their
superiority over tamoxifen in postmenopausal patients with
improved disease-free and overall survival [21, 22]. This has
translated to the neoadjuvant setting too, with several trials
demonstrating superiority of AIs over tamoxifen.
The P024 trial confirmed superiority of 4 months of neo-
adjuvant letrozole over tamoxifen in 337 patients with early
breast cancer who were initially not eligible for breast conser-
vation surgery. Overall objective response rate, determined as
partial or complete response as assessed by clinical palpation,
was 55% with letrozole and 36% with tamoxifen (p < 0.001).
Rate of breast conservation surgery was also superior with
letrozole (45 vs 35%, p = 0.022) [23]. Letrozole also correlat-
ed with a greater reduction in mean Ki67 (87% in letrozole,
75% with tamoxifen) [24]. In ER+HER2+ disease, the supe-
riority of letrozole over tamoxifen was even more significant,
with overall response rates of 88 vs 21%, p = 0.0004 [18].
The Immediate Preoperative Anastrozole, Tamoxifen, or
Combined with Tamoxifen (IMPACT) trial compared neoad-
juvant tamoxifen, anastrozole or both for 3 months, in 330
womenwith ER+ invasive, non-metastatic operable, or locally
advanced but potentially operable breast cancer. There was no
significant difference in objective response rates between the
groups, but there was an increased rate of breast conservation
in the anastrozole group over tamoxifen group (46 vs 22%,
p = 0.03) [25].
In the Preoperative Anastrozole Compared with Tamoxifen
(PROACT) trial, 12 weeks of neoadjuvant anastrozole and
tamoxifen yielded similar response rates by calliper (50 vs
46.2%; OR 1.24, 95% CI 0.84–1.83, p = 0.29) and ultrasound
measures (39.5 vs 35.4%, respectively; OR 1.19, 95% CI
0.82–1.72, p = 0.37) in 451 patients with ER+ large operable
or potentially operable breast cancer. This trial included pa-
tients receiving neoadjuvant chemotherapy at the same time;
and when excluding these, improved response was seen with
anastrozole over tamoxifen (ultrasound response 36.2 vs
26.5%, OR 1.57 (0.97–2.55) p = 0.07; calliper response 49.7
vs 39.4%, OR 1.5 (0.96–2.34) p = 0.08). Additionally, surgi-
cal options were improved. Patients with tumours deemed
inoperable at baseline had improved response with
anastrozole over tamoxifen (ultrasound response 52 vs 29%,
OR 1.81 (1.06–3.11) p = 0.03; calliper response 48.6 vs
35.8%, OR 1.69 (1.03–2.78) p = 0.04) [26].
A Russian study comparing 3 months of neoadjuvant
exemestane to tamoxifen in 151 patients with T2N1–2,
T3N0–1 or T4N0M0 disease confirmed superiority with
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exemestane, with improved clinical response rate (76.3 vs
40%, p = 0.05) and increased breast conservation rate (36.8
vs 20%, p = 0.05) [27].
A meta-analysis of these four trials incorporating 1160
patients confirmed superiority of neoadjuvant AIs over ta-
moxifen in postmenopausal women. Response was superi-
or when assessed by clinical objective response rate (RR
1.29 (1.14–1.47) p < 0.001), ultrasound response rate (RR
1.29 (1.10–1.51) p = 0.002) and breast conserving surgery
rate (RR 1.36 (1.16–1.59) p < 0.001) [28]. Toxicities and
tolerability were similar for all drugs. Similarly, in a sepa-
rate meta-analysis comparing seven trials of neoadjuvant
AIs with tamoxifen, AIs were associated with a significant-
ly higher clinical response rate (OR 1.69 (1.36–2.10)
p < 0.001, n = 1352), radiological response rate (OR 1.49
(1.18–1.89) p < 0.001, n = 1418) and breast conservation
surgery (BCS) rate (OR 1.62,(1.24–2.12) p < 0.001,
n = 918) compared with tamoxifen [9].
Premenopausal Women
There is limited evidence on the role of neoadjuvant endocrine
therapy in premenopausal women. A study assessing 7 days of
pre-operative tamoxifen in 44 patients (58% postmenopausal,
32% pre- or perimenopausal) found a mean decrease in Ki67
of 40% (95% CI 29–63%) [29]. The STAGE trial compared
24 weeks of neoadjuvant anastrozole with tamoxifen in 197
premenopausal women receiving goserelin (gonadotropin-re-
leasing hormone agonist, GnRH). They demonstrated superi-
ority of anastrozole over tamoxifen in attaining complete or
partial response as measured clinically with callipers (70.4 vs
50.5%, p = 0.004), ultrasound (58.2 vs 42.4%, p = 0.027) and
MRI or computed tomography (CT) (64.3 vs 37.4%,
p = 0.032). More patients also achieved breast-conserving
surgery with anastrozole over tamoxifen (86 vs 68%) [30].
Long-term outcomes from both studies are not yet available
however.
Many premenopausal breast cancer patients will have ad-
verse prognostic features, and in general, neoadjuvant chemo-
therapy rather than endocrine therapy in this group is pre-
ferred. The Grupo Español de Investigación del Cáncer de
Mama (GEICAM) study compared neoadjuvant chemothera-
py with 4 cycles of epirubicin and cyclophosphamide follow-
ed by 4 cycles of docetaxel, with neoadjuvant endocrine ther-
apy with 24 weeks of exemestane, in 95 patients with luminal
breast cancer. The cohort included 51 premenopausal patients,
who were randomised to endocrine therapy (exemestane com-
bined with goserelin) or chemotherapy. Clinical response rate
was significantly superior with chemotherapy compared to
endocrine therapy in premenopausal patients (75 vs 44%,
p = 0.027) [31]; however, the rate of BCS was not significant-
ly different (47% with chemotherapy, 56% with endocrine
therapy, p = 0.24). Overall, considering the poorer response
compared to neoadjuvant chemotherapy, there is no
established role for neoadjuvant endocrine therapy in premen-
opausal women.
Choice of Aromatase Inhibitor
The American College of Surgeons Oncology Group
(ACOSOG) Z1031 trial compared the three third-generation
AIs for 16–18 weeks prior to surgery in 377 postmenopausal
women with ER-rich (Allred 6–8) T2–4, N0–3, M0 breast
cancers. They found no significant differences between
anastrozole-, letrozole- and exemestane-treated groups with
objective response rates of 69.1, 74.8 and 62.9%, respectively,
and breast conservation rates of 64, 42.1 and 48.1%, respec-
tively. Rates of down-staging to allow breast conservation
were improved with all AIs with no one drug being superior
[32]. Similar rates of down regulation of ER, PR and reduced
Ki67 have also been shown with short course (14 days) of
anastrozole and letrozole pre-operatively, with no significant
difference between these drugs [33].
Duration of Treatment
Most trials of neoadjuvant endocrine therapy have treated
patients for a duration of between 3 and 6 months.
Prolonging neoadjuvant letrozole beyond this has also been
shown to increase response rates. One study of 182 women
treated with neoadjuvant letrozole described clinical and
ultrasound response after 3 months in 69.8%, which im-
proved to 83.5% in a cohort of 62 patients who continued
letrozole for longer than 3 months. Tumour volume contin-
ued to reduce between 3 and 6 months (median 50%), be-
tween 6 and 12 months (median 37%) and between 12 and
24 months (median 33%). Rate of breast conservation in-
creased from 60 to 72% in those who continued treatment
for longer than 3 months [34].
A further study of 116 ER+ women treated with neo-
adjuvant exemestane found an increase in objective re-
sponse rate with ultrasound and callipers from 47.4% at
16 weeks to 50.9% at 24 weeks. Breast conservation
surgery as assessed by a breast surgeon, was deemed
possible in 49.1% at diagnosis and 76.7% after 24 weeks
of neoadjuvant exemestane [35].
Furthermore, a prospective multicentre trial of 146 patients
treated with neoadjuvant letrozole found that the median time
taken to attain breast conservation surgery was 7.5 months
(95% CI 6.3–8.5 months) [36]. This supports the theory that
longer treatment may provide progressive tumour shrinkage
and may be required to achieve breast conservation surgery. It
is important to closely monitor these patients throughout
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neoadjuvant treatment and switch to surgery or alternative
systemic therapy should there be sign of disease progression.
Neoadjuvant Chemotherapy vs Neoadjuvant
Endocrine Therapy
Comparisons of neoadjuvant chemotherapy and endocrine
therapy are limited reflecting the fact that neoadjuvant chemo-
therapy is less effective in ER+ disease than ER− in achieving
pathological complete response (8% in ER+ cancers com-
pared to 24% of ER−, p < 0.001) [37]. One trial compared
neoadjuvant endocrine therapy (3 months of exemestane or
anastrozole) with neoadjuvant chemotherapy (4 cycles of
doxorubicin and paclitaxel) in 239 postmenopausal women
with ER+ breast cancer. There was no significant difference
in clinical response in endocrine-treated vs chemotherapy-
treated groups (64.5 vs 63.6%) or in mammographic response
(60 vs 63%). There was however a trend in favour of increased
breast conservation in the endocrine-treated rather than
chemotherapy-treated groups (33 vs 24%, p = 0.058) [8].
The GEICAM study compared neoadjuvant endocrine
therapy with chemotherapy in 95 women and demonstrated
superiority of chemotherapy in premenopausal women, as
mentioned above. This was not reflected across the whole
cohort however, with clinical response of 66% with chemo-
therapy vs 48% with endocrine therapy (p = 0.075), and was
even less marked in postmenopausal women, 57% chemother-
apy vs 52% endocrine therapy, p = 0.78 [31].
The Neoadjuvant Endocrine vs Chemotherapy Trial
(NEOCENT) was designed to compare neoadjuvant chemo-
therapy with endocrine therapy in postmenopausal women
with ER-rich (Allred 6–8) tumours. Eighty patients were
randomised to receive 6 cycles of 5-fluorouracil, epirubicin,
and cyclophosphamide or 18–23 weeks of letrozole. They
described similar rates of clinical and radiological response
between the two cohorts; however, the trial closed early due
to slow recruitment and is underpowered; therefore, no signif-
icant conclusions can be drawn [38]. There are few other
prospective trials directly comparing the effects of neoadju-
vant endocrine therapy with chemotherapy [9].
Prediction of Treatment Benefit
The neoadjuvant period provides a unique opportunity to re-
biopsy a tumour on treatment, allowing the exploration of
biomarkers predictive of response and resistance to treatment.
The proliferation antigen Ki67 is an accepted prognostic fac-
tor at baseline [39]. The level of Ki67 after a period of neoad-
juvant treatment [40] is thought to offer a reliable prognostic
estimate. It can correlate with long-term outcome after as little
as 2 weeks of neoadjuvant treatment, as demonstrated in the
IMPACT trial [41]. The limited use of pCR in luminal breast
cancers to neoadjuvant therapy has led to exploration of other
biomarkers, including Ki67, to predict response to treatment
and estimate prognosis.
One study assessed 21-gene recurrence score (RS;
Oncotype DX) at diagnostic core biopsy in 43 patients treated
with neoadjuvant tamoxifen or anastrozole. In those with a
low-risk RS (< 18), response was 64%, compared with 31%
each for both intermediate (19–30) and high RS (> 31). There
was a non-significant trend to improved progression free sur-
vival at 5 years in the low-RS group, compared with interme-
diate and high (100 vs 84%, 73%, respectively, p = 0.14),
although this study is limited by its small cohort [42]. A fur-
ther study assessed OncotypeDx in 116 patients receiving
24 weeks of neoadjuvant exemestane. Clinical response was
significantly higher in patients with a low RS compared with
high RS (59.4 vs 20% p = 0.015). Rate of breast conservation
was also significantly better in low RS vs high RS (90.6 vs
46.7%) [43]. Of note, ER-related genes are heavily weighted
in calculation of the recurrence score.
The Preoperative Endocrine Prognostic Index (PEPI) was
developed from the 228 patient cohort of the P024 trial and
independently validated in the 203 patients in the IMPACT
cohort. PEPI is calculated from tumour size, nodal stage, ER
and Ki67 of the surgical specimen following neoadjuvant en-
docrine treatment, giving a score of 0 (good prognosis), 1–3
(intermediate) and 4+ (poor prognosis) which correlated to
recurrence-free survival (log rank p = 0.002) [44]. PEPI 0
patients with early-stage tumours had no recurrence events
in 5 years in the training cohort, highlighting an excellent
prognostic group who could forego adjuvant chemotherapy.
The currently recruiting ALTERNATE trial will prospectively
assess validity of PEPI in response to anastrozole, fulvestrant
or both.
A 4-gene signature, able to predict response to neoadjuvant
AI based on expression of two genes pretreatment, namely
IL6ST (associated with immune signalling) and NGFRAP1
(apoptosis induction related), and two proliferation genes
(ASPM and MCM4) after 2 weeks of letrozole, has been de-
veloped. This model has a 96% accuracy (96% sensitivity,
94% specificity; positive predictive value 98%, negative pre-
dictive value 89%) [45]. Blinded independent validation in a
second cohort treated with neoadjuvant anastrozole yielded
similar results, predicting response correctly in 40 of 44 pa-
tients; 91% accuracy, 90% sensitivity and 92% specificity.
The 4-gene signature also correlates with progression-free
and breast cancer-specific survival in the training cohort.
Measures of the 4 genes by qRT-PCR and their proteins by
IHC have also been validated, markedly increasing the repro-
ducibility of this test.
The ACOSOG Z1031B study comparing neoadjuvant
letrozole, anastrozole and exemestane assessed an on-
treatment biopsy after 2–4 weeks. If Ki67 was > 10%, patients
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were deemed to be non-responsive to AI and switched to
neoadjuvant chemotherapy or proceeded to surgery. Forty
nine of 236 (20.7%) women had Ki67 > 10% at 2 weeks, of
these 35 switched to chemotherapy, and pathological com-
plete response was achieved in two patients. At 4.4 years fol-
low-up, they also had a significantly increased risk of relapsed
disease (log rank p = 0.004) [46]. Gene expression assessed by
MultiGene Proliferation Score (MGPS) RNA assay demon-
strated even in those with Ki67 > 10% at 2 weeks, the non-
responders, there was still down regulation of MGPS, al-
though to a lesser degree than in those with Ki67 < 10%.
One limitation of this study is the use of pCR to assess re-
sponse to chemotherapy in ER+ tumours, which may explain
the low rate demonstrated. Further survival data is also
awaited.
These studies confirm the added value of an on-treatment
biopsy in predicting response to neoadjuvant endocrine ther-
apy, and indeed long-term outcome. There are several other
ongoing trials looking to prospectively explore this further,
using on-treatment biopsy assessment of response to alter de-
cisions about ongoing treatment.
The trial of Peri-Operative Endocrine Therapy:
Individualising Care (POETIC) is a phase III randomised pro-
spective multicentre trial which recruited 4486 patients over
5 years, comparing 4-week peri-operative AI (2 weeks pre-
and 2 weeks post-operative) with no therapy. The primary
endpoint is to assess outcome in the peri-operative AI group,
over surgery followed by standard adjuvant therapy group. A
secondary outcome is to determine the most effective time
points for molecular profiling, comparing measures of
Ki67 at baseline and at 2 weeks, in prediction of recurrence-
free and overall survival [47]. Recruitment closed in 2014 and
patients are being followed up annually for 10 years.
Combination Therapies
Studies in the metastatic setting have proven the benefit of
combinations of endocrine agents with other endocrine drugs,
or targeted agents, including CDK4/6 inhibitors, and drugs
targeting the PI3K pathway, such as mTOR inhibitors and
pan PI3K inhibitors. These findings are now being translated
into trials of these approaches in the neoadjuvant setting also.
Palbociclib, a CDK4/6 inhibitor, was approved for use in
metastatic ER+ breast cancer by the US Food and Drug
Administration in 2015 following the PALOMA-1 trial, where
in combination with letrozole as first-line therapy in 165
women, it improved progression-free survival from 10.2 to
20.2 months over letrozole alone (p = 0.0004) [48]. In a larger
multicentre cohort in PALOMA-2, there was also improved
progression-free survival with letrozole and palbociclib over
letrozole and placebo as initial treatment in metastatic ER+
disease (24.8 vs 14.5 months, p < 0.001, n = 666) [49]. The
PALTAN study is a phase II neoadjuvant trial of palbociclib in
combination with letrozole and trastuzumab in early ER+
HER2+ breast cancer, which commenced June 2017
(NCT02907918). The toxicities of CDK4/6 inhibitors can be
problematic however, with neutropenia experienced by 75%
of patients in PALOMA-1 and leukopenia in 43%, which may
result in dose reductions and interruptions. Febrile neutrope-
nia is much less common however (< 1.8%) [48, 49]. One aim
of PALTAN is to assess the tolerability and safety of
palbociclib in combination with letrozole and trastuzumab in
the neoadjuvant setting.
The NeoPalAna study assessed neoadjuvant palbociclib
combined with anastrozole in 50 patients with ER+HER2−
disease to assess complete cell cycle arrest (CCCA), defined
as Ki67 < 2.7% after 2 weeks of treatment with both drugs.
CCCA rate was significantly higher after adding palbociclib to
anastrozole (87 vs 26%, p < 0.001) [50]; however, there was a
rebound effect in Ki67 after discontinuation of palbociclib,
suggesting a maintenance treatment may be required.
Neutropenia was experienced in 56% of patients, requiring
seven (3.5%) to have dose reductions.
The NeoMONARCH phase II randomised multicentre
study of 224 patients compared abemaciclib (CDK4/6 inhib-
itor) alone, abemaciclib plus anastrozole, or anastrozole alone
for 2 weeks pre-operatively. Ki67 assessed at baseline and
again at 2-week biopsy was significantly more suppressed at
a 9-month interim analysis with abemaciclib either as mono-
therapy or in combination (p < 0.001, n = 64) than with
anastrozole alone [51]. Again, we await with interest survival
outcomes in these patients.
One study compared 4 months of neoadjuvant letrozole
plus placebo with letrozole plus everolimus (mTOR inhibitor)
in 270 postmenopausal ER+ patients. Clinical response was
superior in the everolimus arm (68.1 vs 59.1%, p = 0.62), as
was a reduction in Ki67 to less than 1%, 57% in everolimus
arm compared with 30% of placebo arm, p < 0.01 [52]. The
toxicity of everolimus may limit its adoption into routine use
in the neoadjuvant setting.
The LORELEI trial is currently ongoing to assess the PI3K
inhibitor, taselisib, combinedwith letrozole in the neoadjuvant
period.
The ALTERNATE trial is a further prospective trial cur-
rently recruiting to compare neoadjuvant anastrozole or
fulvestrant or combination of both, for 6 months in T2–3,
N0–3, M0 ER+HER2− disease. After 4 weeks, Ki67 will be
assessed, and patients switched to neoadjuvant chemotherapy
if > 10%. Patients will continue the same endocrine drug for
adjuvant therapy and PEPI will also be assessed. The primary
objective is to determine whether endocrine resistance (pro-
gressive disease clinically or radiologically) is less with
fulvestrant, or fulvestrant plus anastrozole, than anastrozole
alone. Secondary aims will examine degree of Ki67 suppres-
sion amongst others [53].
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Conclusion
Neoadjuvant endocrine therapy is a suitable treatment for
postmenopausal women with ER-rich, HER2-negative, low-
grade, low proliferative breast cancers. AIs are more effective
than tamoxifen. Duration of treatment should be at least
4 months, but can be extended if necessary to achieve breast
conservation, so long as the patient is monitored for any sign
of disease progression. Repeat biopsy and assessment of on-
treatment Ki67 during neoadjuvant treatment can provide
valuable prognostic information. It is likely in the future that
there will be an increased use of pre- and peri-operative endo-
crine therapy in ER+ disease, as is being explored currently in
POETIC. This could provide valuable prognostic information
and help to guide adjuvant endocrine therapies.
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